Weight-loss Drug Saxenda: Safe and Effective for Obese Children Aged 6 and Above
Weight-loss Drug Saxenda Shows Promise in Young Patients
A new study has revealed that the weight-loss drug Saxenda, approved for treating obesity in adults and teens, is also safe and effective for use in children as young as 6 when combined with diet and exercise. According to the research presented at a medical conference and published in the New England Journal of Medicine, liraglutide has positively influenced key health indicators in children aged 6 to 11.
Study Overview
The trial involved 82 children who received daily injections of liraglutide for nearly 13 months. Results showed a 5.8% reduction in body mass index (BMI) for those on the medication compared to an increase for those on placebos. Furthermore, 46% of the participants showed a BMI decrease of at least 5%, correlated with significant health improvements.
Health Implications
Dr. Claudia Fox noted that prior treatment options for pediatric obesity were limited. The introduction of Saxenda could provide an essential tool in combating childhood obesity, which affects over 20% of U.S. kids. Side effects were common among participants, necessitating careful consideration from healthcare providers.
Looking Forward
The findings could lead to expanded use of Saxenda in younger populations, pending regulatory approval.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.